Safety &Efficacy of CF101 to Subjects With Uveitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01905124|
Recruitment Status : Withdrawn (The company has decided not to conduct the study)
First Posted : July 23, 2013
Last Update Posted : February 1, 2018
|Condition or disease||Intervention/treatment||Phase|
|Uveitis, Posterior Uveitis, Intermediate||Drug: CF101 Drug: Placebo||Phase 2|
This is a Phase 2, randomized, double-masked, placebo-controlled study in adult males and females, aged 18 years and over, with active, sight-threatening, noninfectious intermediate or posterior uveitis. Subjects will be randomly assigned to receive CF101 1 mg or matching placebo tablets in a 2:1 ratio orally every 12 hours for 24 weeks.
At the Screening Visit (performed within 4 weeks prior to Baseline), subjects who provide written informed consent will have a complete medical history, medication history, physical examination, weight, sitting blood pressure, pulse rate, temperature, electrocardiogram (ECG), clinical laboratory tests, and ophthalmologic examination, including biomicroscopy and grading of uveitis activity. For assessment of uveitis activity and response to treatment, fundus photography will be obtained according to a standardized procedure and interpreted at the Uveitis Photograph Reading Center.
Subjects who successfully qualify will begin dosing with CF101 1 mg or placebo, to be taken orally every 12 hours for 24 weeks. At the Baseline Visit, a PBMC sample will be obtained for assessment of A3AR expression level. Subjects will return for safety and efficacy assessments and a new supply of study medication at Weeks 2, 4, 8, 12, 16, 20, and for final assessment and discharge at Week 24. A telephone call to each subject will be made at Week 26, for the purpose of collecting information on adverse events (AEs) and concomitant medications.
During the course of the trial, concomitant use of intraocular or posterior subtenon corticosteroids, intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), systemic corticosteroids at a dose >20 mg/day prednisone equivalent, or monoclonal antibody therapy is prohibited. Systemic corticosteroid and immunosuppressive regimens must remain stable throughout the course of the trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis|
|Estimated Study Start Date :||January 2019|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||October 2019|
Experimental: Drug: CF101
CF101 1 mg q12 hours
CF101 1 mg tablets orally every 12 hours for 24 weeks
Other Name: IB-MECA
Placebo Comparator: Placebo tablets of CF101
Placebo tablets q12 hours
Matching placebo tablets orally every 12 hours for 24 weeks
Other Name: Sugar pills
- Severity of uveitis on standardized photographic assessment [ Time Frame: 24 weeks ]Standardized fundus photographs will be obtained and uniformly assessed in a masked fashion at the Reading Center
- Safety of CF101 [ Time Frame: 24 weeks ]Frequency, nature, and severity of adverse events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01905124
|Bnei-Zion Medical Center|
|Haifa, Israel, 31048|